Bispecific t cell engaging antibody constructs

Patent metadata

Field	Value
Publication number	US-2025163177-A1
Application number	US-202519024730-A
Country	US
Kind code	A1
Filing date	Jan 16, 2025
Priority date	Feb 3, 2016
Publication date	May 22, 2025
Grant date	—

Abstract

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

First claim

1 . An antibody construct comprising at least three domains, wherein:
a first domain binds to a target cell surface antigen, a second domain binds to an extracellular epitope of the human and/or the Macaca CD3ε chain; and a third domain comprises two polypeptide monomers, each comprising a hinge, a CH2 and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker.

2 . The antibody construct of claim 1 , wherein the antibody construct is a single chain antibody construct.

3 . The antibody construct of claim 1 or 2 , wherein said third domain comprises in an amino to carboxyl order:
hinge-CH2-CH3-linker-hinge-CH2-CH3.

4 . The antibody construct of any one of claims 1 to 3 , wherein each of said polypeptide monomers has an amino acid sequence that is at least 90% identical to a sequence selected from the group from the group consisting of: SEQ ID NO: 17-24.

5 . The antibody construct of claim 4 , wherein each of said polypeptide monomers has an amino acid sequence selected from SEQ ID NO: 17-24.

6 . The antibody construct of any one of claims 1 to 5 , wherein the CH2 domain comprises an intra domain cysteine disulfide bridge.

7 . The antibody construct of any one of claims 1 to 6 , wherein
(i) the first domain comprises two antibody variable domains and the second domain comprises two antibody variable domains; (ii) the first domain comprises one antibody variable domain and the second domain comprises two antibody variable domains; (iii) the first domain comprises two antibody variable domains and the second domain comprises one antibody variable domain; or (iv) the first domain comprises one antibody variable domain and the second domain comprises one antibody variable domain.

8 . The antibody construct of any one of claims 1 to 7 , wherein the first and second domain are fused to the third domain via a peptide linker.

9 . The antibody construct according to claims 1 to 8 , wherein the antibody construct comprises in an amino to carboxyl order:
(a) the first domain; (b) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3; (c) the second domain; (d) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 9, 10, 11 and 12; (e) the first polypeptide monomer of the third domain; (f) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7 and 8; and (g) the second polypeptide monomer of the third domain.

10 . The antibody construct according to any one of the preceding claims , wherein the target cell surface antigen is a tumor antigen, an antigen specific for an immunological disorder or a viral antigen.

11 . The antibody construct according to claim 10 , wherein the tumor antigen is selected from the group consisting of CDH19, MSLN, DLL3, FLT3, EGFRvIII, CD33, CD19, CD20, and CD70.

12 . The antibody construct according to any one of the preceding claims , wherein the antibody construct comprises in an amino to carboxyl order:
(a) the first domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 70, 58, 76, 88, 106, 124, 94, 112, 130, 142,160, 178, 148, 166, 184, 196, 214, 232, 202, 220, 238, 250, 266, 282, 298, 255, 271, 287, 303, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, 498, 514, 530, 546, 327, 343, 359, 375, 391, 407, 423, 439, 455, 471, 487, 503, 519, 353, 551, 592, 608, 624, 640, 656, 672, 688, 704, 720, 736, 752, 768, 784, 800, 816, 832, 848, 864, 880, 896, 912, 928, 944, 960, 976, 992, 1008, 1024, 1040, 1056, 1072, 1088, 1104, 1120, 1136, 1152, 1168, 1184, 597, 613, 629, 645, 661, 677, 693, 709, 725, 741, 757, 773, 789, 805, 821, 837, 853, 869, 885, 901, 917, 933, 949, 965, 981, 997, 1013, 1029, 1045, 1061, 1077, 1093, 1109, 1125, 1141, 1157, 1173, 1189, 1277, 1289, 1301, 1313, 1325, 1337, 1349, 1361, 1373, 1385, 1397, 1409, 1421, 1433, 1445; (b) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3; (c) the second domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: SEQ ID NOs: 23, 25, 41, 43, 59, 61, 77, 79, 95, 97, 113, 115, 131, 133, 149, 151, 167, 169, 185 or 187 of WO 2008/119567 or of SEQ ID NO: 15; (d) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 9, 10, 11 and 12; (e) the first polypeptide monomer of the third domain having a polypeptide sequence selected from the group consisting of SEQ ID NOs:17-24; (f) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7 and 8; and (g) the second polypeptide monomer of the third domain having a polypeptide sequence selected from the group consisting of SEQ ID NOs:17-24.

13 . The antibody construct according to claim 12 , having an amino acid sequence selected from the group consisting of:
(a) SEQ ID NOs: 54, 55, 60, and 61; (b) SEQ ID NOs: 72, 73, 78, and 79; (c) SEQ ID NOs: 90, 91, 96, 97, 108, 109, 114, and 115; (d) SEQ ID NOs: 144, 145, 150, 151, 162, 163, 168, 169, 180, 181, 186, and 187; (e) SEQ ID NOs: 198, 199, 204, 205, 216, 217, 222, 223, 234, 235, 240, and 241; (f) SEQ ID NOs: 252, 306, 257, 307, 268, 308, 273, 309, 284, 310, 289, 311, 300, 312, 305, and 313; (g) SEQ ID NOs: 324, 554, 329, 555, 340, 556, 345, 557, 356, 558, 361, 559, 372, 560, 377, 561, 388, 562, 393, 563, 404, 564, 409, 565, 420, 566, 425, 567, 436, 568, 441, 569, 452, 570, 457, 571, 468, 572, 473, 573, 484, 574, 489, 575, 500, 576, 505, 577, 516, 578, 521, 579, 532, 580, 537, 581, 548, 582, 553, and 583; (h) SEQ ID NOs: 594, 610, 626, 642, 658, 674, 690, 706, 722, 738, 754, 77, 786, 802, 818, 834, 850, 866, 882, 898, 914, 930, 946, 962, 978, 994, 1010, 1026, 1042, 1058, 1074, 1090, 1106, 1122, 1138, 1154, 1170, 1186, 599, 615, 631, 647, 663, 679, 695, 711, 727, 743, 759, 775, 791, 807, 823, 839, 855, 871, 887, 903, 919, 935, 951, 967, 983, 999, 1015, 1031, 1047, 1063, 1079, 1095, 1111, 1127, 1143, 1159, 1175, 1191, and 1192-1267; (i) SEQ ID NO: 43; and (j) SEQ ID Nos: 1279, 1280, 1291, 1292, 1303, 1304, 1315, 1316, 1327, 1328, 1339, 1340, 1351, 1352, 1363, 1364, 1375, 1376, 1387, 1388, 1399, 1400, 1411, 1412, 1423, 1424, 1435, 1436, 1447, 1448.

14 . A polynucleotide encoding an antibody construct as defined in any one of claims 1 to 13 .

15 . A vector comprising a polynucleotide as defined in claim 14 .

16 . A host cell transformed or transfected with the polynucleotide as defined in claim 14 or with the vector as defined in claim 15 .

17 . A process for the production of an antibody construct according to any one of claims 1 to 13 , said process comprising culturing a host cell as defined in claim 14 under conditions allowing the expression of the antibody construct as defined in any one of claims 1 to 13 and recovering the produced antibody construct from the culture.

18 . A pharmaceutical composition comprising an antibody construct according to any one of claims 1 to 13 , or produced according to the process of claim 17 .

19 . The pharmaceutical composition of claim 18 , which is stable for at least four weeks at about −20° C.

20 . The antibody construct according to any one of claims 1 to 13 , or produced according to the process of claim 17 , for use in the prevention, treatment or amelioration of a disease selected from a proliferative disease, a tumorous disease, a viral disease or an

Assignees

• Amgen Res Munich Gmbh

Inventors

• Raum Tobias
• Muenz Markus
• Brozy Johannes
• Kufer Peter
• Hoffmann Patrick
• Friedrich Matthias
• Rattel Benno
• Bogner Pamela
• Wolf Andreas
• Pompe Cornelius

Classifications

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/64

  comprising a combination of variable region and constant region components · CPC title

• C07K2317/53

  Hinge · CPC title

• C07K2317/526

  CH3 domain · CPC title

• C07K2317/524

  CH2 domain · CPC title